GHRP-2 (Growth Hormone-Releasing Peptide 2, or Pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin/growth hormone secretagogue receptor (GHS-R). Supplied in a 5 mg vial, it is widely studied for its potent ability to stimulate endogenous Growth Hormone (GH) release, support appetite signaling, and assist in tissue recovery and body composition research.
What Studies Show (Layman Summary):
By acting on central receptors in the hypothalamus and pituitary gland, GHRP-2 triggers significant natural growth hormone spikes. Clinical and preclinical research highlights its potential for:
Potent GH Release: Drives substantial pulses of native Growth Hormone, outperforming earlier secretagogues like GHRP-6 with greater specificity.
Appetite Modulation: Weakly activates ghrelin pathways to moderately stimulate appetite and support weight gain/nutrient intake in catabolic research models.
Tissue Repair & Recovery: Enhances protein synthesis, collagen production, and joint repair downstream via elevated IGF-1 levels.
Fat Metabolism & Lean Mass: Facilitates lipid oxidation while preserving lean muscular tissue during energetic deficit studies.
How It Works (Research Mechanism)
GHRP-2 operates through selective neuroendocrine signaling pathways to drive growth hormone output:
GHS-R Receptor Agonism: Mimics endogenous ghrelin by binding to Growth Hormone Secretagogue Receptors (GHS-R1a) in the anterior pituitary gland and hypothalamus.
Synergistic GHRH Action: Works synergistically when combined with GHRH analogs (such as CJC-1295 or Sermorelin) to amplify total pituitary GH output exponentially rather than linearly.
Somatostatin Inhibition: Suppresses somatostatin (the hormone that inhibits GH release), allowing for uninhibited, robust GH pulses.
Downstream IGF-1 Activation: Drives hepatic production of Insulin-like Growth Factor 1 (IGF-1), the principal mediator of cell growth, tissue repair, and anabolic recovery.
Research Dosing & Usage Parameters
In research protocols, GHRP-2 is evaluated through single or multi-daily administration schedules, often timed around fasting states or post-exercise recovery windows.
Common research parameters evaluate:
Standard Single Test Dose: 100 mcg to 300 mcg per administration.
Daily Frequency: Administered 1 to 3 times per day (e.g., morning, post-research activity, or prior to sleep) on an empty stomach to avoid blunting GH release via elevated blood glucose.
Reconstitution & Concentration Calculation
Adding 2.0 mL of bacteriostatic water or sterile laboratory diluent creates a stock solution concentration of 2.5 mg/mL (250 mcg per 0.1 mL).
Volumetric Ratio Breakdown (with 2.0 mL reconstituted):
0.04 mL (4 units on an insulin syringe) = 100 mcg of active GHRP-2.
0.08 mL (8 units) = 200 mcg of active GHRP-2.
0.12 mL (12 units) = 300 mcg of active GHRP-2.
0.20 mL (20 units) = 500 mcg (0.5 mg) of active GHRP-2.
Storage & Handling Specifications
Store unopened lyophilized vials in a cool, dark environment shielded from direct light exposure. Following reconstitution with bacteriostatic water, maintain stock solutions refrigerated between 2°C – 8°C (36°F – 46°F). Reconstituted stock solutions should be used within 30 days to preserve full biological activity and stability.
